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ABSTRACT 
Aim: To study the clinical relevance and potential mechanism of biomarkers 
in elderly heart failure (HF) patients. 
Methods: A retrospective study was conducted by access to Swedish Heart 
Failure Registry with focus on HF patients aged ≥85 years. A secondary 
study was conducted in our hospital cohort due to acute decompensated HF 
in elderly patients. A prospective study was conducted in elderly patients 
referred for echocardiography because of suspected HF. 
Results: The ≥85 year group from Swedish Heart Failure Registry was 
characterized by higher incidence of cardiovascular and non-cardiovascular 
comorbidities compared with the ≤65 year group. Compared with the 85-90 
year subgroup, the >90 year subgroup had a decline in cardiovascular and 
non-cardiovascular comorbidities. In the secondary study in elderly patients 
during hospital admission due to acute decompensated HF, multivariate 
analysis showed that N-terminal pro-B-type natriuretic peptide (NT-proBNP) 
was not prognostic predictor for all-cause mortality. However, a subgroup 
analysis demonstrated that in patients with NT-proBNP >8000 (ng/L), NT-
proBNP was the only prognostic predictor for all-cause mortality. In the 
prospective hospital cohort referred for echocardiography because of 
suspected HF, red blood cell distribution width (RDW) was higher among 
patients with HF. In three multivariate analyses, biomarkers that were 
prognostic predictors of all-cause mortality were NT-proBNP, cystatin C, 
RDW, midregional pro-atrial natriuretic peptide (MR-proANP). Finally, 
when all the variables that were significant in above three multivariate 
analyses were analyzed in one multivariate analysis the only biomarker that 
 was prognostic predictor of all-cause mortality in elderly HF patients was 
NT-proBNP. Furthermore, the sensitivity and specificity of the two different 
multiple marker modalities are higher than NT-proBNP alone.  
Conclusion: Elderly HF patients had increased cardiovascular and non-
cardiovascular comorbidities that declined from >90 years. The prognostic 
value of NT-proBNP in elderly HF patients has to be interpreted with caution 
due to higher age and comorbidities. Two different multiple marker 
modalities incorporating biomarkers were able to improve prognostic 
prediction compared to NT-proBNP alone. 
Implication: Our studies strongly suggest that the development of multiple 
marker models incorporating biomarkers reflecting different 
pathophysiological pathways might allow for better prognostic prediction in 
elderly HF patients. 
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SAMMANFATTNING 
Ungefär 250,000 patienter har hjärtsvikt i Sverige med en medelålder på 75 
år och ungefär 30,000 nya patienter insjuknar varje år. 
Hjärtsvikt är när hjärta inte orkar pumpa ut tillräckligt med blod till kroppen. 
Det kan antingen bero på att hjärtat är försvagat och har sämre förmåga att 
dra ihop sig och denna typ av hjärtsvikt heter systolisk hjärtsvikt. Eller att 
hjärtat inte fylls tillräckligt med blod innan det pumpas ut till kroppen och 
denna typ av hjärtsvikt heter diastolisk hjärtsvikt. 
Hjärtsviktpatienter kan variera mycket, till exempel i sjukdomsgrad, 
bakomliggande sjukdomar, samsjukligheter och ålder. Dessa faktorer kan 
försvåra diagnosen och prognostisk prediktion av hjärtsvikt hos patienten. 
Efter diagnos är det endast hälften av de äldre hjärtsviktspatienterna som 
lever mer än sex år. För att kunna öka detta behövs dagens prognos förbättras 
och behandlingen individanpassas. De flesta prognosmodeller har utvecklas 
på unga hjärtsviktspatienter och för de äldre patienterna är prognosmodellen 
inte lika utvecklad. Detta beror bland annat på att de äldre 
hjärtsviktspatienterna har oftast mer komplicerade sjukdomsbild med flera 
andra sjukdomar ihop med hjärtsvikten. 
I denna avhandling har vi fokuserat på att hitta prognosmodeller som passar 
äldre patienter med hjärtsvikt och mycket andra sjukdomar. Detta görs genom 
att kombinera olika markörer som analyseras i blodprovet ihop med klinisk 
information. 
Resultatet från denna avhandling är att äldre hjärtsviktspatienter har mera 
hjärtrelaterade och andra sjukdomar jämfört med unga hjärtsviktspatienter. 
Markören som rutinmässigt analyseras i blodprovet för hjärtsvikt, NT-
proBNP, bör användas med försiktigheter pga att NT-proBNP kan variera 
kraftigt hos de äldre hjärtsviktspatienterna till följd av högre ålder och andra 
sjukdomar. Sedan visar denna avhandling också att en kombination av 
markörer ger bättre prognostisk information än bara NT-proBNP ensam. 
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1 INTRODUCTION 
Heart failure (HF) is one of the leading causes of death, and it increases with 
age in line with increased comorbidity and mortality [1-12]. 
Hence, the aim of the work complied in this thesis has been to get a better 
understanding of elderly patients with HF from phenotype characterization to 
prognostic prediction. A multiple marker modality incorporating biomarkers 
is regarded as one of promising ways for a better prognostic prediction in this 
heterogeneous HF population in the elderly and therefore enable individually 
based tailored care. 
1.1 Heart Failure 
Approximately 250,000 patients have HF in Sweden, and the average age is 
75 years. 
HF is when the heart can’t pump out enough blood to the body. It can either 
be because the heart has impaired contractile or pump function and this type 
of HF called systolic heart failure (SHF). Or that the heart has impaired 
relaxation, compliance or filling blood before it is pumped out to the body 
and this type of HF called heart failure with preserved or normal ejection 
fraction (HFNEF). It is common in advanced SHF to have diastolic 
dysfunction as assessed by changes in ventricular filling features. However, 
in general in HFNEF left ventricular systolic performance, contractility and 
function are normal. Most common risk factors for HF are high age, diabetes 
mellitus, hypertension, coronary artery disease and obesity. For SHF 
ischemic heart disease is the most common underlying cause whereas for 
HFNEF it is hypertension. In SHF there are increases in left ventricular 
cavity size, wall stress, wall mass, end-diastolic and end-systolic volumes. In 
the mean time the left ventricular ejection fraction (LVEF) is reduced and the 
thickness of the walls and mass/cavity ratio are either unchanged or 
decreased. In contrast, in HFNEF the cavity size is decreased or unchanged 
and the volumes of the end-diastolic and end-systolic remain normal or 
decreased. However, the wall thickness and mass are usually increased and 
mass/cavity ratio is increased substantially. Systolic wall stress and ejection 
fraction remain normal and end-diastolic wall stress is increased. The major 
mechanism for reduced ejection fraction in SHF is impaired contractile 
function. In HFNEF the functional derangement is impaired left ventricular 
relaxation and increased passive stiffness [13]. 
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HF patients can vary greatly, for example, in disease severity, age, underlying 
diseases and associated diseases. These factors may complicate the diagnosis 
of HF in the patient. 
1.2 Heart Failure in elderly patients 
The number of people with HF aged ≥85 years is increasing rapidly as the 
aged population increases worldwide and this leads to that a more in-depth 
characterization and understanding of HF in this group are needed. HF is one 
of the leading causes of death, and it increases with age in line with 
comorbidity and mortality [1-12]. Comorbidities, for example cerebral 
dysfunction, renal dysfunction, anaemia, diabetes mellitus, liver dysfunction 
and pulmonary diseases frequently accompany HF and further aggravate 
clinical outcome and quality of life. Patients with HF have much higher 
prevalence of comorbidities compared to patients without HF. The 
unresolved issues are the pathophysiological processes that are underlying the 
interactions between comorbidities and HF. Factors associated with HF might 
cause neurohumoral activation, hemodynamic changes and inflammation that 
in turn make HF worse [14]. Braunstein et al. reported that five or more non-
cardiac comorbidities were present in 39% of HF patients. Of all HF patients 
these patients with multiple comorbidities account for 81% of all hospital 
days [15].  
Previous landmark randomized clinical trials have mostly been conducted in 
younger SHF patients. HF patients ≥85 years are rarely studied. Among 
available publications, the so-called “elderly” are mostly aged around 65 
years [1, 5, 9-12, 16] and moreover with limited comorbidities. This leads to 
that HF in patients aged ≥85 years remains poorly understood. Available few 
studies in HF patients aged ≥85 reported inconsistent findings, particularly 
with regard to both cardiovascular and non-cardiovascular comorbidities [6-
9, 17-21]. For instance, the incidence of hypertension has been reported to be 
both lower [18, 20-21] and higher [6-8], and the incidence of ischaemic heart 
disease has been shown to be similar [20], higher [8] and lower in elderly 
patients [7, 18, 21]. These differences may be due to small sample sizes in 
previous studies, a severe limitation because of the highly heterogeneous 
nature of the elderly HF patient population. 
1.3 Biomarkers 
Patients with HF have a poor prognosis, despite advances in treatment. The 
risk of death for patients with HF could only be partly explained by 
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established mortality risk factors such as the New York Heart Association 
functional class, LVEF and N-terminal pro-B-type natriuretic peptide (NT-
proBNP). This is particularly true for elderly individuals, where HF is often 
coexisted with other diseases [15]. In this context we hypothesized that NT-
proBNP alone is not sufficiently enough as prognostic indicator in elderly HF 
patients and additional biomarkers might have added value for more 
accurately predicting the prognosis of HF in elderly populations. Therefore a 
modality of multiple markers might be a novel approach for a better 
prognostic prediction. 
1.3.1 N-terminal pro-B-type natriuretic peptide 
(NT-proBNP) 
In healthy individuals NT-proBNP is normally very low in circulation. In 
cardiomyocytes brain natriuretic peptide (BNP) is activated in response to 
increased myocardial wall stress due to pressure- or volume-overload. This 
leads to that intracellular precursor propeptide is produced. This propeptide is 
further processed and then NT-proBNP and active BNP are released. In HF 
patients NT-proBNP is increased and correlates with severity of HF and 
ventricular wall stress. However, there are other diseases (renal dysfunction) 
and other cardiac diagnoses (valvular heart disease and atrial fibrillation) that 
could influence the NT-proBNP levels as well. SHF and HFNEF cause 
usually elevated NT-proBNP. However, in general HFNEF has lower levels 
of NT-proBNP than that in SHF. There are patients who have NT-proBNP 
level in the gray zone implying that NT-proBNP is slightly elevated above 
cut-off for exclusion for HF and too low to identify HF [23]. Nevertheless 
NT-proBNP is one of few cardiac biomarkers that have been well studied and 
currently recommended by international guidelines for diagnosis and 
prognosis for HF [22]. 
1.3.2 Red blood cell distribution width (RDW) 
Red blood cell distribution width (RDW) is determined during standard 
complete blood count and is a numerical measure of the variability in the size 
of circulating erythrocytes. Normally the erythrocytes are in a standard size. 
However, higher RDW and greater heterogeneity in size of the erythrocytes 
can be caused by ineffective erythropoiesis or increased destruction [24]. 
In several cardiovascular conditions such as HF and coronary artery disease 
[24-32], RDW has been shown to be a strong prognostic predictor. There are 
increasing evidences uniformly supporting the prognostic importance of 
RDW in SHF. Oh et al. reported that in 100 patients admitted to hospital 
because of acute HF there was an independent correlation between RDW and 
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signs on echocardiography of diastolic dysfunction after adjustment for other 
risk factors [33]. Another study by Al-Naijar et al. showed association 
between increasing RDW and worsening heart function in the SHF 
population [26]. 
1.3.3 Multiple marker modality incorporating 
biomarkers  
In HF patients almost half of their deaths are due to non-cardiac origins [15, 
34] and therefore for better prognostic prediction a modality of multiple 
marker incorporating biomarkers has been proposed. There were few studies 
available in approach to multiple marker paradigm. Horwich et al found that 
all-cause mortality and urgent need for cardiac transplantation could be 
improved through combination of troponin-I and BNP in patients with 
advanced HF referred for cardiac transplantation evaluation [35]. Ishino et al 
reported that cardiac death or hospitalization due to worsening of HF were 
reduced in HF patients through combination of BNP, heart-type fatty acid-
binding protein and pentraxin 3 [36]. 
HF has often heterogeneous aetiology and underlying mechanisms covering 
from cardiac overload or injury to a complex interplay among inflammatory, 
genetics, biochemical changes and neurohormonal acting on cardiac 
myocytes, interstitium or both [37]. Because of this a modality of multiple 
biomarkers is needed to represent diverse pathophysiological pathways. 
These pathways include hemodynamic stress (midregional pro-atrial 
natriuretic peptide (MR-proANP) and NT-proBNP); plasma volume and 
osmolarity (copeptin); damage to heart cells (highly sensitive troponin T (hs 
TNT)); inflammation (highly sensitive C-reactive protein (hs CRP)); renal 
function (cystatin C) and RDW [38]. 
Despite above biomarkers have been shown to be predictors for all-cause 
mortality [2, 28-29, 39-42], there are up to now no convincing evidence that 
these novel biomarkers are better than NT-proBNP. Therefore it remains 
unknown whether these new biomarkers are better than NT-proBNP and a 
multiple marker modality incorporating biomarkers is better than a single 
biomarker in elderly HF. 
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2 AIM 
To study the clinical relevance and potential mechanisms of biomarkers in 
elderly HF patients. 
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3 METHODOLOGICAL 
CONSIDERATIONS 
Methods that are used in this thesis are briefly presented here. In each paper a 
more detailed descriptions of methods are provided. 
3.1 Swedish Heart Failure Registry 
The Swedish Heart Failure Registry is an internet-based registry created in 
2003 and allows participating units to register their HF patients online after 
diagnosis by a clinician (www.rikssvikt.se). More than 70 variables, 
including demographics, concomitant diseases, diagnostic procedures, 
hemodynamics, laboratory data and medication are recorded at discharge 
from hospital (within 1 month) or after visits to outpatient clinics [43]. 
Patients ≤65 years and ≥85 years were included in this study. Patients aged 
66–84 years were excluded in this study in order to show the greatest contrast 
as possible between the much younger and much elderly patients. The ≥85 
year group was further divided into two subgroups: 85–90 year and >90 year. 
HF was diagnosed individually by physicians from participating registration 
sites where the current guidelines for the diagnosis and treatment of acute and 
chronic HF is recommended [44-45]. Cut-off for LVEF is defined as <50% in 
SHF, and ≥50% for HFNEF. 
3.2 Patients with acute decompensated 
heart failure 
Patients included in this study were those admitted to Department of 
Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden, due to 
suspect HF during 2005–2007. The current study was based on secondary 
analysis of baseline data from a part of this database with following inclusion 
criteria: age ≥75 years and NT-proBNP immediately taken after hospital 
admission. Outcome data were collected during January–March 2012. HF 
was initially diagnosed individually by physicians on duty in the emergency 
room based mainly on clinical symptoms and signs of HF. HF diagnose was 
confirmed during hospital stay. In current study, HF diagnosis was newly 
adjudicated by two independent cardiologists based on guidelines for the 
diagnosis and treatment of acute and chronic HF [44, 46]. 
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3.3 Patients referred for echocardiography 
Patients referred for echocardiography due to suspected HF at the 
Department of Clinical Physiology, Sahlgrenska University Hospital, 
Gothenburg, Sweden, during 2010 were recruited for present studies. 
Following patients were excluded: patients less than 60 years old in the non-
HF and uncertain HFNEF groups (paper III). 
The diagnosis of SHF was based on HF symptoms in combination with 
LVEF <50% [44]. HFNEF was defined as a combination of four criteria: 1) 
HF symptoms, 2) normal or mild abnormal LVEF ≥50%, 3) non-dilated left 
ventricle and 4) echocardiographic signs of diastolic dysfunction, left atrial 
enlargement, left ventricular hypertrophy and/or NT-proBNP ≥1500 ng/L 
[45]. The non-HF group met the following four criteria: 1) symptoms which 
might be explained by non-cardiac causes, 2) LVEF ≥50%, 3) NT-proBNP 
≤300 ng/L, and 4) absence of left ventricular hypertrophy, left atrial 
enlargement and diastolic dysfunction by echocardiography. As the definition 
of HFNEF remains ambiguous, one group was assigned as uncertain HFNEF 
based on four criteria: 1) HF symptoms, 2) normal or mild abnormal LVEF 
≥50%, 3) echocardiographic signs that only partially fulfilled the diastolic 
dysfunction in absence of left ventricular hypertrophy or left atrial 
enlargement and 4) NT-proBNP <1500 ng/L. 
3.4 Measurement of biomarkers 
The RDW and other blood cell variables were determined using a Model S-
PLUS JR Coulter Counter (Beckman Coulter, INC, USA). The serum levels 
of NT-proBNP and hs TNT were measured by the Elecsys proBNP/hs TNT 
assay (Roche Diagnostics, Indianapolis, INC, USA) except in paper II where 
NT-proBNP was measured using the Stratus proBNP assay (Stratus CS Acute 
Care system, Dade Behring Holdings, INC, USA). MR-proANP was 
analyzed by immunoluminometric assay MR-proANP (B.R.A.H.M.S., 
Germany). Copeptin was analyzed by immunoluminometric assay copeptin 
(B.R.A.H.M.S., Germany). 
All other laboratory variables examined were part of the routine laboratory 
services provided by the Clinical Chemistry Laboratory at Sahlgrenska 
University Hospital. 
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3.5 Collection of clinical data 
Clinical variables were collected either from the Swedish Heart Failure 
Registry or medical records. At the end of the follow-up period, for 
prospective studies, all-cause mortality was collected from medical records 
and the Swedish populations register. 
3.6 Statistical analyses 
Student’s unpaired t-test, Mann-Whitney U-test or One-way ANOVA with 
Bonferroni, and for discrete variables, the chi-square test, were used to assess 
statistical significance. For correlation analysis Spearman and Pearson 
correlations (two-tailed) were used. Stepwise multiple linear regression was 
used for analyzing which factors were independently associated with RDW. 
Both Kaplan-Meier analysis and Cox proportional-hazard regression survival 
model were used for survival analyses. The hazard ratios (HR) with 
confidence intervals (CI) and p-values were presented. Risk score systems 
were established based on Wald X2 values from the Cox proportional-hazard 
regression survival model of variables that were significant in the 
multivariate analyses. 
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4 RESULTS 
4.1 Swedish Heart Failure Registry 
Compared to the ≤65 year group, the 85-90 year group and the >90 year 
group had characteristics that differ. The ≥85 year group was characterized 
by more women, lower BMI, higher systolic blood pressure, lower diastolic 
blood pressure, more left bundle branch block, more than twice as many 
patients with HFNEF compared to the ≤65 year group. Moreover, the ≥85 
year group has more cardiovascular comorbidities (atrial fibrillation, 
ischaemic heart disease and hypertension), more non-cardiovascular 
comorbidities (pulmonary disease, anaemia, renal dysfunction and stroke) 
compared to the ≤65 year group. However, diabetes mellitus decreased with 
ageing (Table 1). 
When comparing the 85–90 year group, in the >90 year group anaemia and 
renal dysfunction increase with age whereas cardiovascular and non-
cardiovascular comorbidities decline (Table 1). In 85-90 year and >90 year 
groups NT-proBNP levels were twice as high as that in ≤65 year group. NT-
proBNP level was also higher in the >90 year group compared to the 85-90 
year group. Moreover, NT-proBNP level was higher in SHF compared to 
HFNEF in the same age group. 
Table 1. Comorbidities in elderly and younger HF patients from the Swedish Heart Failure 
Registry 
Variables ≤65y 85–90y >90y 
 N 8,348 11,412 4,477 
Cardiovascular 
comorbidity 
Ischaemic heart diseases (%) 
Hypertension (%) 
34.8 
37.7 
56.1** 
49.5** 
53.5##,¶¶ 
45.6##,¶¶ 
 Atrial fibrillation (%)1 29.7 57.3** 56.1##,¶ 
 
Non-cardiovascular 
comorbidity 
 
Diabetes mellitus (%) 
Pulmonary diseases (%) 
Stroke (%) 
eGFR <60 (ml/min)2 (%) 
eGFR <30 (ml/min)2 (%) 
24.4 
13.3 
7.9 
10.9 
1.8 
20.0** 
19.1** 
15.7** 
89.8** 
28.0** 
14.6##,¶¶ 
15.5##,¶¶ 
11.3##,¶¶ 
97.2##,¶¶ 
53.1##,¶¶ 
 Anaemia (%)3 22.4 44.3** 47.2##,¶¶ 
1Atrial fibrillation in medical history. 2Estimating glomerular filtration rate (eGFR), Cockroft-
Gaults formula, 3Anaemia according to WHO <130 g/L (male) and <120 g/L (female). 
*p <0.05, **p<0.01 between ≤65 and 85–90 years groups. 
#p <0.05, ##p<0.01 between ≤65 and >90 years groups. 
¶p <0.05, ¶¶p<0.01 between 85–90 and >90 years groups. 
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4.2 Patients with acute decompensated 
heart failure 
When using the multivariate analysis in the HF patients, only pulmonary 
artery pressure (PA) (mmHg), history of valvular surgery and use of 
aldosterone receptor antagonist were significant prognostic indicators for all-
cause mortality. 
HF patients were divided into two subgroups, one with NT-proBNP ≤8000 
(ng/L) and another with NT-proBNP >8000 (ng/L). Multivariate analysis in 
the subgroup with NT-proBNP >8000 (ng/L) demonstrated that NT-proBNP 
was the only significant independent indicator for all-cause mortality. 
However, when the subgroup with NT-proBNP ≤8000 (ng/L) was analyzed, 
enlargement of left atrium and PA (mmHG) were significant prognostic 
indicators for all-cause mortality (Figure 1). 
 
Figure 1. Kaplan-Meier survival curve in patients with NT-proBNP ≤8000 (ng/L)  
(A-B) and NT-proBNP >8000 (ng/L) (C) in the HF cohort. 
The potential impact of NT-proBNP on prognostic prediction in HF patients 
was studied through different levels of NT-proBNP with Kaplan-Meier 
analysis. When NT-proBNP was between 2000-8000 (ng/L) the cumulative 
survival rate was almost the same. However, the cumulative survival rate in 
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group with NT-proBNP ≤8000 (ng/L) was significantly lower than group 
with NT-proBNP >8000 (ng/L). 
4.3 Patients referred for echocardiography 
Compared to the non-HF and with uncertain HFNEF (gray zone patients) the 
mean RDW levels were significantly higher among HF patients. However, 
the mean RDW levels did not differ between SHF and HFNEF. 
A positive correlation between RDW and NT-proBNP and an inverse 
correlation between RDW and LVEF were shown when RDW was divided in 
quartiles. SHF was twice as often in the highest RDW quartile compared to 
the lowest RDW quartile. However, this trend was not significant for 
HFNEF. 
Three multivariate analyses demonstrated that NT-proBNP, cystatin C, 
RDW, MR-proANP, PA (mm Hg), estimated glomerular filtration rate 
(eGFR), anaemia, sinus rhythm and diuretics were significant predictors of 
all-cause mortality. However, when all above variables that were significant 
was analyzed in one multivariate analysis, only NT-proBNP, eGFR <60 
(ml/min), anaemia and diuretics remained significant predictors for all-cause 
mortality. 
The potential impact of NT-proBNP on prognostic prediction in HF patients 
was studied through different levels of NT-proBNP with Kaplan-Meier 
analysis. When NT-proBNP was between 2000-8000 (ng/L) the cumulative 
survival rate was almost the same and the cumulative survival rate was 
significantly lower in group with NT-proBNP ≤8000 (ng/L) than group with 
NT-proBNP >8000 (ng/L). 
According to Wald X2 values from the univariate or the multivariate analyses, 
risk score systems were set up. In HF patients a score ≤2 indicates lower 
mortality risk, score 3-5 indicates intermediate risk and ≥6 indicates higher 
mortality (Figure 2). 
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Figure 2. Kaplan-Meier survival curve (A) and ROC curve (B) in patients with 
different levels of NT-proBNP (ng/L) in the HF cohort. Kaplan-Meier survival curve 
(C) and ROC curve (D) in patients with different levels of score in score system 1 in 
the HF cohort. Kaplan-Meier survival curve (E) and ROC curve (F) in patients with 
different levels of score in score system 2 in the HF cohort. 
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5 DISCUSSION 
5.1 Clinical phenotype of heart failure in 
the elderly vs study population 
There were limited studies available in HF patients ≥85 years, most studies 
were in younger populations. The HF patients ≥85 years are estimated to 
constitute one-fourth of the HF population aged >65 years [9]. 
One study in HF patients ≥85 was Euro Heart Failure Survey II [6], however 
in this study there were not so many HF patients ≥85 years. In other studies 
there were not so many HF patients ≥85 years either [7, 21]. This might 
explain why previous findings about relations between ageing and incidences 
of comorbidities have not been consistent [6-9, 17-21]. Therefore our study is 
needed, since our sample size is almost 20 times larger in HF patients ≥85 
years compared with previous studies [6, 7, 21]. According to our results, in 
HF patients ≥85 years there were increases in most of the cardiovascular and 
non-cardiovascular comorbidities compared with the ≤65 year group. 
Moreover most of the cardiovascular and non-cardiovascular comorbidities 
were declined in the >90 year group compared with the 85-90 year group. 
However, there were comorbidities that continuously increase with age: renal 
dysfunction and anaemia. Therefore our study has extended previous findings 
about difference between elderly and younger through its large sample size. 
In this thesis the population from prospective study should be regarded as 
representative as they are characterized by higher age, multiple comorbidities 
and a 2-year all-cause mortality in 25%, which was almost 8 times higher 
than those with non-HF. Regarding group with uncertain HF, it seems that 
many of them did not have HF since its all-cause mortality is less than 1/3 of 
HF group. This group with uncertain HF is quite large and constitutes about 
17% of study population, indicating indeed an utmost challenge in HFNEF 
diagnostic in our daily clinical practice in particular in the elderly. In our 
retrospective studies, HF populations were decompensated hospitalized 
patients and were included without exclusions. Therefore they are also 
representative. As a complimentary to our retrospective studies, our 
prospective study are partly hospitalized and partly from Outpatient Clinic in 
one hand, and partly decompensated and partly stable in other hand. It is 
interesting to stress that it is important and clinically relevant to study such a 
heterogeneous population because HF in nature is extremely heterogeneous. 
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What is most important to point out is that in our prospective study all 
electrocardiogram, blood sampling and clinical examination were performed 
within approximately 24 hours from the time point when echocardiography 
was performed. To our knowledge most of previous clinical trials had 
echocardiography within 3-6 months prior to trials whereas in registry 
database or retrospective studies longer time in months or years could occur 
between echocardiography and biomarker analyses. 
5.2 Prognostic value of NT-proBNP in 
elderly heart failure patients 
In younger HF, NT-proBNP is a well-established prognostic biomarker [38, 
41, 47-49]. However NT-proBNP is difficult for interpretation in the elderly 
partly because there are huge individual variations in particular when 
comorbidity is present, and partly because NT-proBNP increases 
dramatically with age. Our studies showed that only in a subgroup with NT-
proBNP >8000 (ng/L), NT-proBNP was a significant prognostic indicator in 
those ≥75 years with acute decompensated HF. However, in the elderly HF 
patients referred for echocardiography NT-proBNP was significant in the 
multivariate analyses. This might be due to that patients with decompensated 
HF had more hemodynamic disturbance compared to the HF patients referred 
for echocardiography. Another factor could be that those elderly HF patients 
with decompensated HF had a mean follow-up by 5 years whereas HF 
patients referred for echocardiography had a mean follow-up only for 2 years.  
Our results are in line with previous results. Several studies demonstrated that 
NT-proBNP was a prognostic indicator for mortality only in univariate but 
not in multivariate analyses in HF populations [41, 50]. Another study 
showed that NT-proBNP was significant in the multivariate analysis [42] in a 
similar HF population as elderly HF patients referred for echocardiography in 
our study. 
Our results emphasized that in terms of prognostic value in the elderly, NT-
proBNP level needs to be much higher than those in younger, in particular 
during acute decompensation. Therefore the prognostic value of NT-proBNP 
should be taken with caution when its level ≤8000 (ng/L) [2]. 
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5.3 Prognostic value of a multiple marker 
modality incorporating biomarkers 
It remains unknown whether new biomarkers are better than NT-proBNP in 
elderly HF patients. Therefore we analyzed a panel of biomarkers including 
both novel biomarkers and established NT-proBNP. 
In this thesis we have demonstrated that all biomarkers in our study had 
significant associations with all-cause mortality in the univariate analyses in 
HF patients. However, in the three multivariate analyses only four 
biomarkers (NT-proBNP, cystatin C, RDW and MR-proANP) were 
significantly associated with all-cause mortality. Our results are in line with 
previous reports [28-29, 40, 42, 48-49, 51-54]. However when all above four 
biomarkers were analyzed in one multivariate analysis, the only biomarker 
that was significant for all-cause mortality was NT-proBNP. 
Furthermore we were able to compare two different multiple marker 
modalities incorporating NT-proBNP and NT-proBNP alone in prognostic 
prediction. As shown by ROC curves in our study, the areas of ROC curves 
from two different score systems are higher than that using different levels of 
NT-proBNP. This is believed to be clinically relevant for those patients with 
NT-proBNP level between 2000-8000 (ng/L). 
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6 CONCLUSION 
In HF patients most cardiovascular and non-cardiovascular comorbidities 
increase with age and decline in HF patients >90 years. 
The prognostic value of NT-proBNP in elderly HF patients has to be 
interpreted with caution due to higher age and comorbidity. 
In HF patients two different multiple marker modalities incorporating 
biomarkers were able to improve prognostic prediction compared to NT-
proBNP alone. 
Our studies strongly suggest that the development of multiple marker 
modality incorporating biomarkers reflecting different pathophysiological 
pathways might allow for better prognostic prediction in elderly HF patients. 
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